PTCT
PTC Therapeutics Inc

4,290
Mkt Cap
$5.24B
Volume
1.23M
52W High
$87.50
52W Low
$35.95
PE Ratio
8.19
PTCT Fundamentals
Price
$62.82
Prev Close
$63.33
Open
$62.41
50D MA
$73.43
Beta
1.19
Avg. Volume
1.17M
EPS (Annual)
$7.78
P/B
-25.13
Rev/Employee
$1.75M
$5,161.47
Loading...
Loading...
News
all
press releases
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
KROS advances rinvatercept for Duchenne muscular dystrophy, with a phase II trial planned for 2026 after gaining FDA orphan drug designation.
Zacks·12h ago
News Placeholder
More News
News Placeholder
Royce & Associates LP Has $2.01 Million Holdings in PTC Therapeutics, Inc. $PTCT
Royce & Associates LP lessened its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 34.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·19h ago
News Placeholder
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
Key PointsAdded 41,303 shares of PTC Therapeutics; estimated trade size $3.00 million based on quarterly average pricing...
Nasdaq News: Markets·4d ago
News Placeholder
Oversold Conditions For PTC Therapeutics (PTCT)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...
Nasdaq News: Markets·5d ago
News Placeholder
JPMorgan Chase & Co. Reduces Holdings in PTC Therapeutics, Inc. $PTCT
JPMorgan Chase & Co. lowered its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 18.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund...
MarketBeat·6d ago
News Placeholder
GSA Capital Partners LLP Decreases Position in PTC Therapeutics, Inc. $PTCT
GSA Capital Partners LLP trimmed its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 82.8% during the 3rd quarter, according to the company in its most recent filing with the...
MarketBeat·8d ago
News Placeholder
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are presently covering the company...
MarketBeat·8d ago
News Placeholder
PTC Therapeutics, Inc. $PTCT Holdings Decreased by Vanguard Group Inc.
Vanguard Group Inc. lessened its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 6.3% in the third quarter, according to its most recent filing with the Securities & Exchange...
MarketBeat·9d ago
News Placeholder
16,062 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Private Capital Advisors Inc.
Private Capital Advisors Inc. acquired a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and...
MarketBeat·9d ago
News Placeholder
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 3,019 Shares
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 3,019 shares of the business's stock in a transaction on Thursday, February 19th. The stock was sold at an average...
MarketBeat·11d ago
<
1
2
...
>

Latest PTCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.